Talking with your healthcare provider about Qsymia®
(phentermine and topiramate extended-release) capsules

Qsymia® is for adults with a BMI* of 30 or more† and should be used with a reduced-calorie diet and increased physical activity for chronic weight management.

The discussion of weight is a very personal topic. Now that you’re ready to speak with your healthcare provider about losing weight with Qsymia®, you want to be prepared for that conversation. Here are some discussion points to help you get started.

Starting the Conversation

Use the suggestions below as a guide to discussing Qsymia with your healthcare provider:

- Begin your discussion by sharing your interest in losing weight and the reasons why you’re ready for a prescription weight-loss option
- Ask your healthcare provider if he/she will help you achieve your weight-loss goals
- Ask your healthcare provider if you are the right patient type to use Qsymia
- Ask your healthcare provider what to expect when using Qsymia
  - How much weight can I expect to lose with Qsymia?
  - Are there any side effects?
  - What nutrition and lifestyle changes will I have to make to give me the best chance at success?
- Ask your healthcare provider to write 2 prescriptions:
  1. Qsymia starter dose, 2-week supply
  2. 30-day supply of recommended dose
- Agree with your healthcare provider when your next follow-up appointment should be scheduled

NOTES:

Your healthcare provider may be interested in information about Qsymia. We recommend that you share the following pages of this pdf. This page can be printed or bookmarked on your Smartphone.

* BMI (body mass index) measures the amount of fat in the body based on height and weight. BMI is measured in kg/m².
† Or a BMI of 27 or more with one weight-related medical condition.

IMPORTANT SAFETY INFORMATION

Do not take Qsymia if you are pregnant, planning to become pregnant, or become pregnant during Qsymia treatment; have glaucoma; have thyroid problems (hyperthyroidism); are taking certain medicines called monoamine oxidase inhibitors (MAOIs) or have taken MAOIs in the past 14 days; are allergic to topiramate, sympathomimetic amines such as phentermine, or any of the ingredients in Qsymia. See the end of the Medication Guide for a complete list of ingredients in Qsymia.

Please see the Qsymia Important Safety Information on page 3 of this document, and the Full Qsymia Prescribing Information at www.Qsymia.com.
Support your patient’s weight-loss effort

Qsymia is proven to provide and sustain significant weight loss
Patients with a BMI* of 35+ lost more than 4x the number of pounds on the recommended dose of Qsymia® compared to diet and exercise alone.†

<table>
<thead>
<tr>
<th>(N=614) Placebo</th>
<th>6 lbs</th>
</tr>
</thead>
<tbody>
<tr>
<td>(N=278) Phentermine 7.5mg / Topiramate 46 mg</td>
<td>25 lbs</td>
</tr>
</tbody>
</table>

*BMI (body mass index) measures the amount of fat in the body based on height and weight. BMI is measured in kg/m².
†Qsymia was studied in a large trial supporting FDA approval, which involved 2,487 people whose BMI was 27 or greater with 2 or more weight-related medical problems such as high blood pressure or diabetes. The combined number of people with a BMI of 35 or greater, and used in the subset analysis, was 1,493 (Placebo patients = 614, Phentermine 7.5 mg/Topiramate 46 mg patients = 278, Phentermine 15 mg/Topiramate 92 mg = 601). In this trial, it was recommended that patients eat a well-balanced diet and reduce their caloric intake by 500 kcal/day. Your results may vary depending on your BMI, diet, activity, dose of Qsymia, and other factors.

Qsymia is an FDA-approved, clinically proven prescription weight loss medication. Depending on dose, patients in clinical trials who stayed on Qsymia for one-year lost an average of 22-28 pounds.

- Qsymia is a once-daily medicine taken orally
- Qsymia is a patented, extended-release formulation combining phentermine and topiramate—2 well-known, previously approved medications
- This medication requires an initial titration dose. For more information, go to www.qsymia.com/hcp or contact VIVUS medical information at 1-888-998-4887

IMPORTANT SAFETY INFORMATION

LIMITATIONS OF USE:
- It is not known if Qsymia changes your risk of heart problems or stroke or of death due to heart problems or stroke
- It is not known if Qsymia is safe and effective when taken with other prescription, over-the-counter, or herbal weight loss products
- It is not known if Qsymia is safe and effective in children under 18 years old

Please see the Qsymia Important Safety Information on the next page of this document, and the Full Qsymia Prescribing Information at www.qsymia.com.
Qsymia dosing

<table>
<thead>
<tr>
<th>STARTING</th>
<th>RECOMMENDED</th>
<th>TITRATION</th>
<th>TOP</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.75 mg/23 mg</td>
<td>7.5 mg/46 mg</td>
<td>11.25 mg/69 mg</td>
<td>15 mg/92 mg</td>
</tr>
</tbody>
</table>

PRESCRIBING INSTRUCTIONS
For appropriate patients, 2 prescriptions are recommended at their first weight-management appointment
1. Qsymia starter dose, 2-week supply
2. 30-day supply of recommended dose

• Monthly follow-up visits with your patients taking Qsymia are recommended to monitor progress

INDICATION
Qsymia should be used together with a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of:
• 30 kg/m2 or greater (obese) or
• 27 kg/m2 or greater (overweight) in the presence of at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol

LIMITATIONS OF USE:
• It is not known if Qsymia changes your risk of heart problems or stroke or of death due to heart problems or stroke
• It is not known if Qsymia is safe and effective when taken with other prescription, over-the-counter, or herbal weight loss products
• It is not known if Qsymia is safe and effective in children under 18 years old

IMPORTANT SAFETY INFORMATION
Do not take Qsymia if you are pregnant, planning to become pregnant, or become pregnant during Qsymia treatment; have glaucoma; have thyroid problems (hyperthyroidism); are taking certain medicines called monoamine oxidase inhibitors (MAOIs) or have taken MAOIs in the past 14 days; are allergic to topiramate, sympathomimetic amines such as phentermine, or any of the ingredients in Qsymia. See the end of the Medication Guide for a complete list of ingredients in Qsymia.

Qsymia can cause serious side effects, including:
Birth defects (cleft lip/cleft palate). If you take Qsymia during pregnancy, your baby has a higher risk for birth defects called cleft lip and cleft palate. These defects can begin early in pregnancy, even before you know you are pregnant. Women who are pregnant must not take Qsymia. Women who can become pregnant should have a negative pregnancy test before taking Qsymia and every month while taking Qsymia and use effective birth control (contraception) consistently while taking Qsymia. Talk to your healthcare provider about how to prevent pregnancy. If you become pregnant while taking Qsymia, stop taking Qsymia immediately, and tell your healthcare provider right away. Healthcare providers and patients should report all cases of pregnancy to FDA MedWatch at 1-800-FDA-1088, and the Qsymia Pregnancy Surveillance Program at 1-888-998-4887.

Please see the Qsymia Important Safety Information on the next page of this document, and the Full Qsymia Prescribing Information at www.Qsymia.com.
IMPORTANT SAFETY INFORMATION (CONTINUED)

Increases in heart rate. Qsymia can increase your heart rate at rest. Your healthcare provider should check your heart rate while you take Qsymia. Tell your healthcare provider if you experience, while at rest, a racing or pounding feeling in your chest lasting several minutes when taking Qsymia.

Suicidal thoughts or actions. Topiramate, an ingredient in Qsymia, may cause you to have suicidal thoughts or actions. Call your healthcare provider right away if you have any of these symptoms, especially if they are new, worse, or worry you: thoughts about suicide or dying; attempts to commit suicide; new or worse depression; new or worse anxiety; feeling agitated or restless; panic attacks; trouble sleeping (insomnia); new or worse irritability; acting aggressive, being angry, or violent; acting on dangerous impulses; an extreme increase in activity or talking (mania); other unusual changes in behavior or mood.

Serious eye problems, which include any sudden decrease in vision, with or without eye pain and redness or a blockage of fluid in the eye causing increased pressure in the eye (secondary angle closure glaucoma). These problems can lead to permanent vision loss if not treated. Tell your healthcare provider right away if you have any new eye symptoms.

Possible side effects of Qsymia include:

Mood changes and trouble sleeping. Qsymia may cause depression or mood problems, and trouble sleeping. Tell your healthcare provider if symptoms occur.

Concentration, memory, and speech difficulties. Qsymia may affect how you think and cause confusion, problems with concentration, attention, memory or speech. Tell your healthcare provider if symptoms occur.

Increases of acid in bloodstream (metabolic acidosis). If left untreated, metabolic acidosis can cause brittle or soft bones (osteoporosis, osteomalacia, osteopenia), kidney stones, can slow the rate of growth in children, and may possibly harm your baby if you are pregnant. Metabolic acidosis can happen with or without symptoms. Sometimes people with metabolic acidosis will: feel tired, not feel hungry (loss of appetite), feel changes in heartbeat, or have trouble thinking clearly. Your healthcare provider should do a blood test to measure the level of acid in your blood before and during your treatment with Qsymia.

Low blood sugar (hypoglycemia) in people with type 2 diabetes mellitus who also take medicines used to treat type 2 diabetes mellitus. Weight loss can cause low blood sugar in people with type 2 diabetes mellitus who also take medicines used to treat type 2 diabetes mellitus (such as insulin or sulfonylureas). You should check your blood sugar before you start taking Qsymia and while you take Qsymia.

High blood pressure medicines. If you are taking medicines for your blood pressure, your doctor may need to adjust these medicines while taking Qsymia.

Central Nervous System (CNS) side effects. The use of prescription sleep aids, anxiety medicines, or drinking alcohol with Qsymia may cause an increase in CNS symptoms such as dizziness and light-headedness. Do not drink alcohol with Qsymia.

Possible seizures if you stop taking Qsymia too fast. Seizures may happen in people who may or may not have had seizures in the past if you stop Qsymia too fast. Your healthcare provider will tell you how to stop taking Qsymia slowly.

Please see the Qsymia Important Safety Information on the next page of this document, and the Full Qsymia Prescribing Information at www.Qsymia.com.
IMPORTANT SAFETY INFORMATION (CONTINUED)

Kidney stones. Drink plenty of fluids when taking Qsymia to help decrease your chances of getting kidney stones. If you get severe side or back pain, and/or blood in your urine, call your healthcare provider.

Decreased sweating and increased body temperature (fever). People should be watched for signs of decreased sweating and fever, especially in hot temperatures. Some people may need to be hospitalized for this condition.

Common side effects of Qsymia include:
Numbness or tingling in the hands, arms, feet, or face (paraesthesia); dizziness; changes in the way foods taste or loss of taste (dysgeusia); trouble sleeping (insomnia); constipation; and dry mouth.

Tell your healthcare provider if you have any side effect that bothers you or does not go away. These are not all of the possible side effects of Qsymia. For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to VIVUS, Inc. at 1-888-998-4887 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please read the Qsymia Medication Guide and Full Prescribing Information.

The Q and Me™ Patient Support Program is based on the LEARN® Program provided under copyright license (September 15, 2010). All rights reserved.

VISIT QSYMIA.COM FOR MORE INFORMATION